// App-Quantinova.ai

111 : Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.

Researchers

Presenter

  • Holger N. Lode

Principal Investigators

  • Hans Loibner

  • Sascha Troschke-Meurer

  • Dominique Valteau Couanet

  • Alberto Garaventa

  • Juliet Gray

  • Victoria Castel

  • Isaac Yaniv

  • Nikolai Siebert

  • Christin Eger

  • Madlen Juettner

  • Silke Kietz

  • Karoline Ehlert

  • Evelyne Janzek

  • Ina Mueller

  • Ruth Ladenstein

Medical Centers

  • University Medicine Greifswald, Greifswald, Germany

  • Apeiron Biologics AG, Vienna, Austria

  • Pediatric and Adolescent Oncology, Gustave Roussy Institute, Universite Paris-Sud, Villejuif, France

  • G Gaslini Children's Hospital, Genova, Italy

  • University of Southampton, Southampten, United Kingdom

  • Pediatric Hematology and Oncology, Pediatric Oncology Unit Hospital La Fe Valencia, Valencia, Spain

  • Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel

  • Apeiron Biologics AG, Vienna, Austria

  • St. Anna Children's Hospital and Research Institute for the SIOP Europe Neuroblastoma Group, Paediatric Haematology/Oncology, Vienna, Austria

Locations

  • Germany

  • Austria

  • France

  • Italy

  • United Kingdom

  • Spain

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Clusterin

  • DNA Damage Inducible Transcript 3

  • Human leukocyte antigen Bw4

  • Interleukin-2

Drug/Treatment

  • ch14.18

  • APN-311

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved